← Markets

Arcus Biosciences, Inc.

RCUS · NYSE

Market closed$27.37$0.730000 (+2.74%)After hours $27.50 · +0.48%

Key statistics

Previous close$26.64
Open$25.99
Day high$27.84
Day low$25.68
52-week high$31.74
52-week low$8.84
Market cap2.76B
Volume781.58K
Average volume1.33M
P/E ratio-8.41
Forward P/E—
EPS-3.26
Dividend yield0.00%

Market context

Why it moved

RCUS shares moved higher likely driven by positive sentiment or sector rotation within biotech, as broader market sources indicate chip stocks were under pressure, potentially redirecting investor interest toward healthcare and oncology-focused names like Arcus Biosciences.

InstagramFinvizComTiktokYelp

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Arcus Biosciences tumbled nearly 5%, pulling back from recent highs as insider selling weighed on sentiment — co-founder and President Juan C. Jaen sold 68,569 shares for ~$2.03 million on July 9–10 under a Rule 10b5-1 plan, just below the stock's 52-week high of $31.73 following a 201% run over the past year. The decline came despite Truist Securities initiating coverage with a Buy rating and a $35 price target, citing casdatifan's best-in-class potential in renal cell carcinoma, while the broader healthcare sector (XLV) held relatively steady and the S&P 500 dipped modestly amid tech-driven selling pressure.

-4.9251

July 15, 2026Arcus Biosciences closed modestly lower, weighed by continued investor scrutiny following Co-Founder and President Juan C. Jaen's sale of 68,569 shares (~$2.03M) under a Rule 10b5-1 plan at prices between $28.61–$30.05 — near the stock's 52-week high of $31.73 after a ~201% one-year run. While the planned nature of the sale limits its signal, it arrives alongside a Q1 earnings miss (EPS of -$1.02 vs. -$0.85 expected) and an InvestingPro overvaluation flag, tempering sentiment even as Truist Securities recently initiated coverage with a Buy rating and $35 target, citing casdatifan's promising profile in renal cell carcinoma.

-1.0942

July 14, 2026Arcus Biosciences edged higher as investors weighed a notable insider sale disclosure against continued pipeline optimism. President Juan C. Jaen sold 68,569 shares (~$2.03M) under a pre-arranged Rule 10b5-1 plan at prices between $28.61–$30.05, though he retained over 1.2 million shares. Bullish sentiment around lead candidate casdatifan in renal cell carcinoma persists, supported by a recent Nature publication and Truist Securities' Buy rating with a $35 price target, even as Q1 results missed estimates and the broader healthcare sector faces headwinds.

0.9263

July 14, 2026Arcus Biosciences fell amid a confluence of company-specific and macro headwinds, with the stock still digesting Gilead Sciences' recent decision to walk away from its partnership — a significant blow given Gilead's deep financial and strategic ties to the company. Adding to the pressure, president Juan C. Jaen sold approximately $2 million in shares under a pre-arranged 10b5-1 plan, a visible insider transaction that drew investor attention. Broader market sentiment was also negative, with U.S. equities declining as renewed U.S.-Iran military tensions sent oil prices surging and weighed on risk appetite.

-2.9391

July 8, 2026Arcus Biosciences edged higher and extended gains in after-hours trading, buoyed by continued investor enthusiasm following Nature's publication of ARC-20 study data linking deeper HIF-2α inhibition with improved outcomes in metastatic kidney cancer — a catalyst that has driven a ~31% 30-day price surge. The biomarker-linked efficacy signal for casdatifan has reinforced the company's late-stage RCC narrative, with analysts estimating a fair value of ~$35.75 — roughly 18% above current levels — while a June 2026 collaboration with Bristol Myers Squibb to add casdatifan to the ROSETTA RCC-208 trial adds further strategic credibility. Broader sector tailwinds, including Jim Cramer calling biotech "the hottest group in the market" amid a more favorable M&A environment, are supporting sentiment.

0.9006

July 6, 2026Arcus Biosciences edged lower in regular trading but is recovering in after-hours, as investors continue to digest the Nature-published ARC-20 study data for casdatifan, its HIF-2α inhibitor for metastatic renal cell carcinoma. The publication, which links deeper serum EPO suppression to higher response rates and longer progression-free survival, has reignited valuation debate — with fair value estimates around $35.75 suggesting ~18% upside — while a June 2026 collaboration with Bristol Myers Squibb to incorporate casdatifan into the ROSETTA RCC-208 trial underscores growing partner confidence in the program. Broader healthcare sector weakness weighed on the stock during the session.

-1.154

July 3, 2026Arcus Biosciences surged nearly 5% as investors responded to a landmark Nature publication validating the company's lead kidney cancer drug casdatifan. The study, drawn from the ARC-20 trial, demonstrated a compelling link between HIF-2α inhibition, serum EPO suppression, and clinical outcomes — with a pooled analysis of 121 patients showing a median progression-free survival of 12.2 months despite heavy prior treatment. The results reinforce casdatifan's best-in-class profile heading into the Phase 3 PEAK-1 study, bolstering Wall Street's constructive stance with analyst consensus price targets around $35.75. Healthcare was also the top-performing S&P sector on the day, providing a tailwind.

4.8755

July 2, 2026Arcus Biosciences shares tumbled after the stock pulled back from near 52-week highs, even as the company announced a high-profile Nature publication validating casdatifan's clinical profile in kidney cancer, showing a 12.2-month median progression-free survival in a heavily pre-treated metastatic ccRCC population. The sell-off — on above-average volume — appears to reflect a classic 'sell the news' dynamic following the stock's 269% run over the past year, compounded by a broader tech- and chip-led market decline on July 1 and lingering concern over Arcus's Q1 miss. In after-hours trade, shares edged slightly off the session lows as investors digested the casdatifan data alongside a new Truist buy rating with a $35 price target.

-6.1953

Simply Wall Street · July 5, 2026Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In FocusSimply Wall Street · July 3, 2026How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker DataBioSpace · April 21, 2026Gilead, Arcus tumble again in TIGIT, triggering 2 trial cullsInvestor's Business Daily · December 12, 2025Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning StreakBioPharma Dive · December 12, 2025Arcus cancels work on Gilead-partnered cancer combo after trial setbackInvestor's Business Daily · October 7, 2025Can This Small Biotech Take On Merck In Cancer?
Mt Newswire · July 13, 2026Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing
Benzinga · July 1, 2026Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney Cancer
Mt Newswire · June 24, 2026Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing
Mt Newswire · June 3, 2026Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
Benzinga · June 3, 2026Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor
Benzinga · May 18, 2026Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35
Benzinga · May 11, 2026Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22
Benzinga · May 7, 2026Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34

Peers

S&P 500SPX · $7,457.69-1.01%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%Merck & Co., Inc.MRK · $127.50-0.10%Roche Holding AGRO.SW · 339.60+0.83%Gilead Sciences, Inc.GILD · $134.28-1.48%AstraZeneca PLCAZN · $168.90-0.23%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Axsome Therapeutics, Inc.AXSM · $230.00-2.97%Agenus Inc.AGEN · $5.01+0.20%Syndax Pharmaceuticals, Inc.SNDX · $22.80+0.40%Corvus Pharmaceuticals, Inc.CRVS · $14.90+4.41%Relay Therapeutics, Inc.RLAY · $19.91+2.79%